Vol. 21/No. 1 | OncologyLive

Advanced Practitioners Improve Oncology Care Value

January 12, 2020

The aging of the baby boomer population and the growing number of cancer survivors have created a huge demand for oncology treatment services. Centers for Medicare & Medicaid Services has compounded the need by ratcheting up standards for value-based care. To handle these additional needs, many oncology practices now turn to advanced practice providers, typically nurse practitioners or physician assistants, who are highly trained and capable of taking over many of the routine functions of the oncology clinic.

Role of Immunotherapy Agents Grows in Metastatic Colorectal Cancer

January 11, 2020

The standard of care in the second line for patients with mismatch repair–deficient metastatic colorectal cancer has shifted to favor therapy utilizing immunotherapeutic agents, according to Howard Hochster, MD.

SITC Poised to Expand Toolkit of Immunotherapy Guidelines

January 11, 2020

The Society for Immunotherapy of Cancer is developing a growing menu of guidelines with treatment algorithms for specific cancer types to help practicing oncologists navigate the appropriate use of this emerging modality.

T-Cell Immunotherapy Pioneer Seeks New Direction for Solid Tumors

January 11, 2020

CAR T cells are a highly active field of investigation, with many companies at work on formulations they hope to bring to market, but these agents have limitations, particularly with metastasized solid tumors.

Experts Take Stock of Frontline Immunotherapy Combos in NSCLC

January 09, 2020

During an OncLive Peer Exchange program, an international panel of lung cancer experts provided perspective on key findings regarding various immune checkpoint inhibitor (ICI) combinations and data concerning potential biomarkers of response to ICIs in non–small cell lung cancer.

Zanubrutinib Faces Off Against Ibrutinib in CLL Trial

January 08, 2020

Armed with the knowledge that inhibition of the Bruton tyrosine kinase is an effective approach in B-cell malignancies, investigators will explore the efficacy of the second-generation BTK inhibitor, zanubrutinib, in 2 leukemia and lymphoma subtypes.

Patient Tragedy Inspires Program Focused on Immune-Related Toxicities

January 08, 2020

The advent of immunotherapy options to treat patients with cancer has brought with it a new wave of immuno-related toxicities. One institution, Massachusetts General Hospital, has taken steps to establish an immunotherapy toxicity service care team, inspired by a 65-year-old patient with metastatic melanoma that had spread to his lungs and brain.

On the Radar for 2020: Oncology Experts Weigh In on Key Trends

January 07, 2020

After witnessing 10 years of breakthroughs across the spectrum of cancer care, oncology experts are looking ahead as a new decade begins to capitalize on those wide-ranging therapeutic and diagnostic gains.

Success Breeds a Need for Oncology Trials That Tackle Real-World Questions

December 30, 2019

Placing the results of a single trial in the context of real-world, everyday practice is increasingly difficult because of the number of available options and the absence of studies that directly compare individual strategies.

Pazdur Followed the Pathway of Greatest Resistance to the FDA

December 30, 2019

Richard Pazdur, MD, set out to be a leader in medicine and a teacher of doctors. He achieved that and more, turning the oncology drugs section of the FDA from a poorly understood and lead-footed division into a fast-moving and patient-responsive entity.